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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the effectiveness of digital adherence interventions for improving adherence to maintenance treatments in asthma.
B A C K G R O U N D
Description of the condition
Asthma is the most common chronic lung condition worldwide,
affecting 334 million adults and children globally (Global Asthma
Report 2014); it accounts for an estimated 400,000 deaths each
year (Soriano 2017). Asthma can cause shortness of breath, chest
tightness, and cough and typically presents with wheezing. Many
people with asthma experience intermittent worsening of their
asthma symptoms, known as ’exacerbations’, ’flare-ups’, or ’at-
tacks’ (GINA 2016). Attacks can be triggered by common irri-
tants and allergens such as pollution, tobacco smoke, pollen, and
house dust mites (CDC 2016). Asthma is often incorrectly di-
agnosed - both overdiagnosed and underdiagnosed - worldwide
(Aaron 2017; Looijmans-van den Akker 2016; Nolte 2006; van
Schayck 2000); treatment remains suboptimal. Most asthma-re-
lated deaths occur in middle- and low-income countries. Poorly
controlled asthma places a huge burden on individuals, their fam-
ilies, and society (WHO 2013).
Asthma treatment falls into two categories - maintenance preven-
tive treatment for long-term control of symptoms and prevention
of asthma attacks, and more immediate short-term relief for acute
management of symptoms and attacks (BTS/SIGN 2016). This
review focuses on maintenance preventive treatment. The main-
stay of asthma maintenance treatment for all but the mildest cases
consists of regular inhaled corticosteroids (ICSs) (Barnes 1993),
which are also commonly referred to as ’preventer’ or ’controller’
medications (i.e. the intention is that they are used once or twice
daily (depending on the preparation), even when the patient is
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well, to maintain control over symptoms). ICSs, which are de-
livered directly to a patient’s airways via an inhaler or a nebu-
liser, work by suppressing the multiple inflammatory cascades that
are activated in the airways of a person with asthma. Inflamma-
tion leads to increased mucus production and airway constric-
tion, which in turn contribute to the symptoms of asthma. Re-
duction in underlying inflammation through sustained use of an
ICS can result in symptom improvement and reduced asthma-re-
lated morbidity and mortality (Barnes 2003; Barnes 2015). Com-
monly used ICSs include budesonide, beclomethasone, fluticas-
one (propionate and furoate),mometasone, and ciclesonide. These
can be given alone or in combination with other maintenance
asthma medications such as long-acting beta2-agonists (LABAs),
leukotriene receptor antagonists (LTRAs), long-acting muscarinic
antagonists (LAMAs), theophylline, and slow-release beta2-ago-
nist tablets (BTS/SIGN 2016). LABAs are add-on therapies that
are used only in combination with an ICS, in separate or com-
bination inhalers. LABAs work by keeping the airways open and
relaxing themuscles of the airways but do not treat any underlying
inflammation. As such, LABAs should be used only with an ICS
- never alone. Examples of LABAs include formoterol and salme-
terol. LTRAs are usually considered as add-on therapies to ICS
or ICS plus LABA, although evidence for use of LTRAs is based
largely on studies in which LTRA was added to an ICS. LTRAs
work by blocking the effects of cysteinyl leukotrienes in the air-
ways - these leukotrienes are released during asthma attacks and
cause bronchoconstriction. Addition of LTRA to an ICS may lead
to improvements in asthma symptoms and lung function (Joos
2008). LTRAs are usually given orally as a tablet formulation; the
most common example is montelukast. In adults with asthmawho
do not respond to ICS and LABA, LAMAs such as tiotropium
may be considered as add-on treatment. Other alternative add-on
maintenance options include theophyllines or slow-release beta2-
agonist tablets (for adults only), whichmay improve lung function
and symptoms. In patients with a high steroid burden who con-
tinue to have frequent asthma attacks, symptoms, and impaired
lung function, injectable maintenance treatment with monoclonal
antibodies may be considered. Anti-immunoglobulin (Ig)E mon-
oclonal antibody injections such as omalizumab bind to free cir-
culating IgE, thus reducing free IgE levels. This is given as a sub-
cutaneous injection every two to four weeks. Anti-interleukin-5
monoclonal antibody injections such as mepolizumab have been
examined by researchers yet remain unlicensed for use in many
countries (BTS/SIGN 2016).
Despite availability of medical treatment, adherence to ICSs is
suboptimal, with patients needing to take treatment every day,
regardless of whether they have symptoms (Barnes 2015; Lasmar
2009;Williams 2004). ’Adherence’ is defined by theWorldHealth
Organization (WHO) as “the extent to which a person’s behaviour
(such as taking medication) corresponds with the agreed recom-
mendations from a healthcare provider” (WHO 2003). Current
adherence rates reported in the literature range from 0 to 100%,
varying between and within individuals, but are estimated to av-
erage around 50% (McDonald 2002; Nieuwlaat 2014; WHO
2003). Adherence rates are estimated to be even lower in high-risk
populations such as ethnicminority groups (Mathes 2014), as well
as in developing countries (McQuaid 2012). Poor adherence to
asthma maintenance treatment - in particular ICSs - is associated
with increased morbidity and mortality. An estimated 383,000
asthma deaths have been reported worldwide (WHO 2013). In
the UK, the National Review of Asthma Deaths found that 67%
of asthma deaths were due to avoidable factors such as patients not
taking their prescribed asthma medication in the month and/or
year before their death (Royal College of Physicians 2014), high-
lighting non-adherence as a key modifiable determinant of mor-
tality. Poor adherence is associated with considerable asthma-re-
lated morbidity: The risk of an asthma exacerbation is more than
three times higher in patients after cessation of low-dose inhaled
corticosteroids (Ebmeier 2017).
Investigators have identified several reasons for poor adherence,
depending on the type of non-adherence. Broadly speaking, non-
adherence can be classified as unintentional or intentional non-
adherence. In unintentional non-adherence, patients do not ad-
here to prescribed treatment owing to factors not directly within
their control, such as difficulties with medication-taking or access
to treatment (Clifford 2008;Horne 2005; Kardas 2013). In inten-
tional non-adherence, the patient makes a conscious decision to
not take themedication; the patient chooses to not adhere owing to
certain beliefs about treatment or perceptions of asthma (Clifford
2008), such as concerns around side effects of ICSs or lack of per-
ceived personal need for treatment (Cooper 2015; Howell 2008;
Menckeberg 2008; Ponieman 2009; Van Steenis 2014).
Description of the intervention
This review focuses on digital adherence interventions. No uni-
formdefinition of ’digital’ can be found in the literature, andmuch
overlap is evident between different classifications of digital in-
terventions. In this review, ’digital’ refers to interventions that are
delivered via an online (web-based) platform (e.g. websites, web
applications, online forums); a computer-based platform (e.g.mo-
bile apps, shortmessage service (SMS)-based interventions, games,
interactive voice recognition systems (IVRSs)); or an electronic de-
vice of any type (e.g. electronic adherencemonitoring devices).We
will exclude from the review solely telephone-based interventions
(e.g. health professional phone calls, telemonitoring, telehealth).
Online platforms
Online platforms, otherwise known as web-based platforms, in-
clude websites, web-based apps, and online forums; this term de-
scribes any intervention administered through a web browser on-
line and requiring internet connectivity for delivery of the inter-
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vention. These can be targeted to individuals or groups of indi-
viduals.
Computer-based platforms
This term describes any intervention that is delivered through
computer-based platforms - such as via mobile, tablet, or desktop
interfaces - and does not require internet connectivity for delivery
of the intervention (Bussey-Smith 2007; Johnson 2016). These
generally fall under the category of mobile applications, SMS-
based interventions, or computer programmes or games.
Mobile apps
’Mobile apps’ refer to software programmes designed for smart-
phones and tablets. Apps are optional add-ons to mobile devices
that interact with users via a set of interfaces (e.g. a visual user
interface). Asthma mobile apps usually aim to promote adherence
by supporting overall asthma self-management skills, as through
reminders or feedback on adherence (Marcano Belisario 2013).
Apps can have many functions, including communication and
collection of information from users and provision of interactive
experiences. They provide a platform for delivery of adherence in-
terventions that are considered to be highly customisable, of low
cost, and easily accessible (Dayer 2013). However, challenges sur-
round the use of mobile apps for delivery of adherence interven-
tions. Engagement rates are often low, with few users download-
ing and using mobile apps on a regular and long-term basis, and
concerns around privacy and data management remain (Anderson
2016; Krebs 2015).
SMS-based interventions
Most short message service (SMS)-based interventions aim to im-
prove adherence by sending messages as reminders for medica-
tion-taking (Ali 2014; Kannisto 2014); with some interventions
use SMS to deliver educational or behavioural messages to mobile
phones (Tran 2014). The approach is usually low cost and may
be customisable to address adherence barriers unique to each in-
dividual. A recent meta-analysis reported that use of SMS-based
interventions to improve adherence could potentially double the
odds of adherence across various chronic diseases (Thakkar 2016).
The capability of SMS to relay information to many people with-
out delay was cited by study authors as a key reason for exploring
the potential of SMS-based interventions for adherence (Thakkar
2016).
Computer games or programmes
Computer games or programmes have been used increasingly as
a method of intervention to drive changes in health behaviours
(Johnson 2016). Interactive programme- or game-based inter-
ventions are postulated to be effective for influencing behaviour
through their ability to motivate and stimulate engagement, par-
ticularly for children and adolescents. For asthma, game-based ap-
proaches have been used with some success to improve ICS adher-
ence (Bussey-Smith 2007; Krishna 2003; Mosnaim 2015). These
have ranged from simple games to educate and reinforce adher-
ence behaviour (Mosnaim 2015), to complex interactive multime-
dia programs incorporating animation and scenarios of vignettes
targeted to individuals or groups (Krishna 2003). However, diffi-
culties with production and associated high costs are barriers that
have limited their adoption and use in practice (Johnson 2016).
Interactive voice response systems
Interactive voice response (IVR) systems constitute a type of com-
puter-linked telephone intervention system that uses several tech-
nologies to schedule, make, receive, or record automated phone
calls, which can be used to promote adherence. IVR systems can
be programmed to make and receive automated phone calls, ask
questions, obtain feedback, and provide individualised informa-
tion. Information can be tailored according to responses given
through voice recognition or a touchtone keypad, and these sys-
tems have been used in several adherence interventions (Bender
2010; Reidel 2008).
Electronic monitoring devices
Electronic adherence monitoring devices (EMDs) have the abil-
ity to electronically record doses taken. EMDs can be used with
different medication delivery devices including inhalation devices
and pill bottles. Most EMDs measure, at minimum, the date and
time of dosing, although more sophisticated devices are able to
track the GPS location of doses, provide a customisable user inter-
face, wirelessly transmit data to a linked mobile app, and provide
dosing reminders (Chan 2013). EMDs can be used in adherence
interventions as stand-alone devices or as part of a wider inter-
vention. EMDs can track adherence patterns over time, and these
can be shared with the patient and the healthcare provider via
the device or through generated reports. Whilst EMDs can track
the time and date of dosing, few can record inhalation or actual
medication-taking. New devices such as the Inhaler Compliance
Assessment (INCA) can record the sounds of inhalation (D’Arcy
2014); however the accuracy of this recording, whilst good, is still
not perfect (Taylor 2018).
How the intervention might work
Digital interventions offer advantages in terms of adaptiveness, ac-
cessibility, reproducibility, and reach.Owing to the widespread use
of digital technology, digital interventions can reach a large num-
ber of people, particularly in settings where access to either non-
digital materials or face-to-face consultations is restricted (Masoli
2004). The ease of accessing digital technologies such as online
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platforms, websites, and mobile phone apps may promote en-
gagement with the adherence intervention (Baptist 2016; Dayer
2013). Digital interventions can also promote better communi-
cation between patients and healthcare providers (Dayer 2013;
Eakin 2012). Digital interventions can support monitoring and
recording of medication usage, asthma symptoms, or lung func-
tion, or all of these. Data can be fed back to patients in real time
or communicated to their healthcare provider, thus facilitating a
seamless transfer of health information across all interfaces of care
(Chan 2013). This enables healthcare providers to gain access to
detailed adherence information, which can provide insights into
their patient’s adherence behaviour that they may not otherwise
have. This can add value to consultations by opening up conversa-
tions about adherence and drawing on actual, rather than assumed,
adherence (Eakin 2012; Riekert 2002). Healthcare providers can
be better equipped to provide recommendations personalised to
the patient’s behaviour. Patients can have the opportunity to reflect
on the adherence data and their medication-taking behaviours,
and to see how their adherence may be linked to their asthma
control. For example, they may be able to identify patterns in
their medication use that may be related to particular adherence
barriers, allowing them to understand how this behaviour may be
associated with their asthma symptoms.
Digital interventions also offermany interactive opportunities that
non-digital interventions do not. This fact may enhance their ef-
fectiveness compared with non-digital interventions, which have
limited interactivity and are primarily static, as patients may find
digital media or interactive interfaces more engaging (Johnson
2016). Compared with traditional paper-based media, digital in-
terventions can support the delivery of information in a variety
of media formats that can be tailored to the patient’s information
preferences, thus increasing accessibility of the information in dif-
ferent populations (Baptist 2016). For example, users can choose
how they want information to be presented to them, such as via
a video animation or through text, and what kind of information
they want. This ability to tailor can help target both unintentional
non-adherence (e.g. through use of personalised reminders tai-
lored to the individual’s medication-taking routine (Britto 2012))
and intentional non-adherence (e.g. through use of messages sent
to target and change negative beliefs or perceptions (Petrie 2012)).
Digital technologies thus have the potential to deliver accurate in-
formation to patients in a timely manner, in a way that can be tai-
lored to patients’ healthcare needs and beliefs, and to provide prac-
tical medication support such as reminders and alarms. Besides
improving engagement, use of different media can help increase
the accessibility of health information for patients who may find
traditional media (such as patient information leaflets) difficult
to engage with - for example, patients with poor health literacy
or visual or aural impairments, or those with learning disabilities
such as dyslexia (Baptist 2016).
Digital intervention has been found to have issues that need to be
considered before these methods are taken up and adopted into
practice. These include concerns around data privacy, issues re-
lated to information governance such as accountability and liabil-
ity around identification of non-adherence, ownership of adher-
ence data, cost, impact on health disparities in terms of differences
in ease of digital accessibility, and uncertainties around how best to
incorporate digital interventions into existing workflow and health
systems and how to train healthcare providers to respond to or
use the collected information and how best to engage populations
effectively (Anderson 2016; Krebs 2015; Michie 2017).
Why it is important to do this review
Medication non-adherence is one of the major health challenges
facing modern medicine; poor medication adherence is associ-
ated with increased morbidity, mortality, and healthcare costs. In
asthma, adherence to maintenance treatment such as ICS as the
mainstay of treatment averages around 50%, although in some
populations it can be as low as 20%, depending on the population
and the method used to measure adherence (Sulaiman 2016; van
Dulmen 2007; WHO 2003).
Poor adherence leads to significant morbidity in the form of poor
asthma control, hospitalisations, days off work, and death (Suissa
2000; WHO 2003; Williams 2004). Many studies have high-
lighted the importance of good adherence in asthma - for example,
Suissa et al found that the rate of death from asthma decreased
by 21% for each additional canister of ICS used in the previous
year (Suissa 2000); likewiseWilliams et al reported that every 25%
increase in ICS use leads to 11% decreased risk of asthma exacer-
bations (Williams 2011).
In the UK, non-adherence to preventer treatment has been re-
ported to be a factor contributing to approximately one-third of
asthma deaths in one year (Levy 2014; Royal College of Physicians
2014). Interventions to improve adherence however have demon-
strated limited effectiveness of adherence and assessment of out-
comes (Nieuwlaat 2014). Part of the challenge of non-adherence is
the difficulty involved in measuring adherence accurately and reli-
ably. A range of methods are available to assess adherence directly
(e.g. through direct observation ofmedication-taking or blood lev-
els) or indirectly (e.g. via prescription or refill records, self-report,
or electronic monitoring devices). However, all of these methods
have their own advantages and disadvantages and can be subject
to error (Farmer 1999).
Therefore it remains unclear how delivery of interventions can
best support patient adherence to prescribed treatments. A shift
within health care suggests that patients increasingly wish to take
an active role in self-managing their own health and making their
own healthcare decisions; this shift is driving the need for patients
to be fully informed so they canmake informed healthcare choices.
Digital technologies, such as web and mobile platforms and elec-
tronic adherence devices, have been used increasingly as part of ad-
herence interventions. Widespread use of smartphones and tablet
computers provides a great opportunity for their use in delivery of
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adherence interventions. Early evidence suggests that certain digi-
tal technologies - such as electronic reminder systems (Tran 2014)
- may be effective in improving adherence, but questions remain
around the size of this effect, and whether certain characteristics
of digital interventions influence their effectiveness.
A recentCochrane review focusing on interventions to improve ad-
herence to ICS in asthma reported that adherence education, elec-
tronic trackers or reminders, and simplified regimens showed bet-
ter adherence than controls (Normansell 2017). This review pro-
vided important information highlighting that electronic track-
ers or reminders may be effective in improving adherence. How-
ever, the review classification of ’electronic tracker or reminders’
did not allow differentiation between the different types of dig-
ital interventions, and likewise, digital interventions (e.g. inter-
active voice recognition systems) were included under adherence
education (Normansell 2017). More information is needed to de-
termine whether certain types of digital interventions are more
effective than others. The review was also restricted to only ICS
as a medication class; to effectively answer the question around
whether digital interventions can be effective for medication ad-
herence behaviour in general, it would be useful to explore all
classes of maintenance medication beyond ICSs. Adherence inter-
ventions also vary in terms of whether or not they are grounded
in health psychology theory; recent evidence suggests that inter-
ventions that are behaviourally targeted and guided by theory may
be more effective than those that are not (Conn 2017; Holmes
2014).Whether this applies to digital-based interventions remains
unknown. Understanding whether use of theory is associated with
more effective digital interventions is also important for this re-
view - to inform future intervention development.
O B J E C T I V E S
To determine the effectiveness of digital adherence interventions
for improving adherence to maintenance treatments in asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) including
cluster- and quasi-randomised trials. We will exclude cross-over
trials and will include studies reported in full text, those published
as abstract only, and unpublished data.
Types of participants
We will include both adults (aged 18 years and over) and children
(under 18 years) with a diagnosis of asthma, as per international
or national guidelines, or whose condition was diagnosed by a
healthcare professional and are currently prescribed maintenance
asthma treatment (via any administration route), given alone or in
combination with other controller therapies. We will include in-
terventions that target parents or carers who are involved in man-
agingmaintenance asthmamedication for any participant.Wewill
exclude interventions that are targeted at healthcare professionals,
as the review relates only to digital interventions targeted at pa-
tients.
We will exclude participants with the following co-morbidities/
characteristics.
1. Other respiratory comorbidities such as chronic obstructive
pulmonary disease (COPD) or bronchiectasis.
Wewill include studies inwhich only a subset of participantsmeets
the inclusion criteria (asthma diagnosis, prescribed maintenance
treatment, or managing maintenance treatment for a participant
diagnosed with asthma) if we can obtain disaggregated data.
Types of interventions
We will include studies comparing any interventions with a pri-
mary or secondary aim of improving adherence to maintenance
asthma treatment (alone or in combination) that uses:
1. a digital component to deliver the intervention versus non-
digital delivery of the same adherence intervention; or
2. a digital component to deliver an intervention versus usual
care. Usual care is defined as standard asthma care as per
evidence-based guidelines or standard care in the study setting.
Included digital interventions may be completely self-delivered or
may include an ’in-person’ or ’human’ element whereby a health-
care professional or a trained peer is involved in the intervention.
This can occur at the point of invitation to participate (e.g. intro-
duction of the digital intervention and/or training of the patient
to use the digital intervention) or on an ongoing basis (e.g. discus-
sion of data from the digital intervention at regular consultations,
use of remote adherence monitoring and feedback to the patient).
The interventions may be delivered completely virtually (i.e. com-
pletely digital with no ’in-person’ element) or may include some
face-to-face aspect (i.e. has an ’in-person’ element); delivery can be
provided to individuals (e.g. with mobile apps or electronic mon-
itoring) or to groups (e.g. online forums or computer games), and
the intervention may be delivered on a one-off or ongoing basis.
We will include the following cointerventions, provided they are
not part of the randomised treatment.
1. Cointerventions for which more than one type of digital
media is used.
2. Other cointerventions that are used in asthma management
When interventions have been described in insufficient detail to
determine how the digital intervention was used, we will contact
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the authors of identified studies to obtain further information. In
the case of non-response after initial contact, we will follow up
with study authors twice (once every two weeks), if required. If
we receive no response after three contacts, we will exclude these
studies from the review.
Types of outcome measures
Primary outcomes
1. Adherence to maintenance medication as assessed by any
objective or validated subjective measure of adherence
2. Asthma control as determined by any validated self-report
instrument
3. Exacerbations requiring at least oral corticosteroid
treatment (prescribed or taken - as measured by self-report or via
objective measurement, e.g. from pharmacy dispensing or
prescription records)
We have chosen these primary outcomes as these measures are the
most likely outcomes to be used.
Secondary outcomes
1. Acceptability of the digital intervention (using any
validated instrument or quantitative measure of acceptability
such as dropout rates, proportion, of days on which tools were
used, satisfaction with the intervention). We will exclude
qualitative data or patient feedback.
2. Unscheduled healthcare utilisation (number of visits to a
healthcare provider/attendance at an emergency department or
urgent care centre/hospital admission (i.e. overnight stays))
3. Time off school, work, or other commitments due to
asthma exacerbations or complications
4. Lung function as measured by peak expiratory flow rate
(PEFR)
5. Quality of life as assessed by any validated standard
instrument
6. Cost-effectiveness of the intervention (via any reported
cost-effectiveness outcome such as impact on hospitalisation/
length of stay)
7. Adverse events
If outcomes are reported at multiple time points, we will extract
these and will include the latest reported time point. We will ex-
clude post-intervention follow-up data. If multiple measures of
adherence are used, we will include the most objective measure in
the review.
Reporting in the study of one or more of the outcomes listed here
is not an inclusion criterion for this review.
Search methods for identification of studies
Electronic searches
We will seek assistance from the Cochrane Airways Information
Specialist to identify studies from the Cochrane Airways Trials
Register, which is maintained by the Information Specialist for the
Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP (1946 to date).
3. Weekly searches of Embase Ovid SP (1974 to date).
4. Monthly searches of PsycINFO Ovid SP (1967 to date).
5. Monthly searches of Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO (1937 to date).
6. Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. We will
include details of these strategies, as well as a list of handsearched
conference proceedings, in Appendix 1. See Appendix 2 for search
termsused to identify studies for this review.These termshave been
guided by previousCochrane reviews such as theNormansell 2017
review (which identifies asthma adherence reviews, although we
will not be restricting to inhaled corticosteroids) and the Marcano
Belisario 2013 review (which focused on smartphone and tablet
apps, although we will not be restricting the review to only these
two digital media).
We will search the following trials registries.
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We will search the reference lists of all primary studies and review
articles for additional references.
We will search for studies from the year 2000, as technologies ex-
isting before this time are unlikely to be representative of contem-
porary technologies that support health apps - this is in line with
the Cochrane smartphone app review by Marcano Belisario et al
(Marcano Belisario 2013).
We will apply no language restrictions.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references.We will search relevant manufac-
turers’ websites for study information.
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We will search for errata or retractions from included studies pub-
lished in full text on PubMed and will report within the review
the date this was done.
Data collection and analysis
Selection of studies
Two review authors (AC, ADS) will independently screen the titles
and abstracts of the search results and will code them as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’.We will
retrieve the full-text study reports of all potentially eligible studies,
and two review authors (VW,CC) will independently screen them
for inclusion, while recording the reasons for exclusion of ineligible
studies. We will resolve any disagreement through discussion, or,
if required, we will consult a third person/review author (LH).
We will identify and exclude duplicates and will collate multiple
reports of the same study, so that each study, rather than each
report, is the unit of interest in the review. We will record the
selection process in sufficient detail to complete a PRISMA flow
diagram and ’Characteristics of excluded studies’ table (Moher
2009).
Data extraction and management
We will use Rayyan (Ouzzani 2016) to screen titles and abstracts
of identified studies based on the aforementioned inclusion crite-
ria. We will then obtain full-text study reports/publications of in-
cluded or potentially relevant studies, and two review authors will
independently screen these to identify studies for inclusion and to
identify and record reasons for exclusion of ineligible studies. We
will resolve disagreements through discussion or, if not resolved,
by consultation with the review team. We will exclude any dupli-
cates and multiple reports of the same study.
Wewill useCovidence to extract study characteristics and outcome
data. We will develop a data collection form to extract data and
will pilot this form on at least one study in the review. Two review
authors (from the following: AC, ADS, VW, LH, and CC) will
extract the following study characteristics from included studies
in duplicate.
1. Methods: date of study, study design and method of
randomisation, length of follow-up, total study duration, details
of any ’run-in’ period, number of study centres and locations,
study setting (healthcare setting and country), study withdrawals
(study dropout and intervention dropout). We will attempt to
distinguish between study versus intervention dropouts to better
understand attrition behaviour, if possible, as per an earlier
review (Sohanpal 2012)).
2. Participants: N (baseline and upon completion), mean age,
age range, gender, severity of asthma, baseline lung function,
smoking history, inclusion criteria, exclusion criteria, and
differences between groups at baseline.
3. Interventions: intervention details, type of intervention
(theory-based vs non-theory-based), details of intervention
provider, intervention target (primary and secondary), types of
digital components used (technologies used), number of digital
components, number of intervention sessions, interactivity with
patient (i.e. a two-way flow of information between the digital
component and the patient), adherence feedback, concomitant
medications, and excluded medications.
4. Comparison: details of comparison group.
5. Outcomes: primary and secondary outcomes specified and
collected; methods of assessment of outcomes and time points
reported.
6. Notes: funding of trial and notable conflicts of interest of
trial authors.
Two review authors (from the following: AC, ADS, VW, LH,
and CC) will independently extract outcome data from included
studies. We will note in the ’Characteristics of included studies’
table if outcome data were not reported in a usable way. We will
resolve disagreements by consensus or by involving a third person/
review author (RH). One review author (AC) will transfer data
into the Review Manager file (RevMan 2014). We will double-
check that data are entered correctly by comparing data presented
in the systematic review against study reports. A second review
author (VW) will spot-check study characteristics for accuracy
against the study report.
Assessment of risk of bias in included studies
Two review authors (from the following: AC, VW, ADS, and LH)
will assess risk of bias independently for each study using the cri-
teria outlined in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We will resolve any disagreements
by discussion or by involving another review author (CC).We will
assess risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will judge each potential source of bias as high, low, or unclear
and will provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes when necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). When information on
risk of bias relates to unpublished data or correspondence with a
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trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and will justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
For data reported as rates or times-to-events (e.g. exacerbations),
we will analyse time-to-event or rate ratios. Reported rate ratios
can be transformed into log-rate ratios and analysed via a random-
effects model and by generic inverse variance (GIV).
We will analyse continuous data as standardised mean differences
(SMDs) using a random-effects model and 95% confidence inter-
vals (CIs). We will use mean differences (MDs) rather than SMDs
however if measures are reported on the same scale, but we antic-
ipate that most studies will use a variety of methods of measure-
ment, in which case we will use the SMD.Wewill use the standard
deviation (SD) of final (rather than baseline) measurements in the
analysis. Although adherence can be presented as dichotomous or
continuous, adherence generally is best considered as a continuous
variable by nature (to avoid loss of valuable information and use
of arbitrary cutoffs), which may be later dichotomised, depend-
ing on the adherence measurement method used (Saberi 2011).
Therefore, we will treat adherence as continuous data in this re-
view, and this will increase the power to detect a difference. We
can adjust dichotomous data by applying a logit transformation
and producing an SMD, which can be analysed via GIV. When
available, we can use change from baseline scores.
We will undertake meta-analyses only when this is meaningful,
that is, when treatments, participants, and the underlying clinical
question are similar enough for pooling tomake sense, for example,
studies using a similar method of digital intervention. We will
describe skewed data narratively (e.g. as medians and interquartile
ranges for each group).
When a single study reports multiple trial arms, we will include
only the relevant arms. If two comparisons (e.g. intervention A vs
control and intervention B vs control) are combined in the same
meta-analysis, we will combine the active arms or will halve the
control group to avoid double-counting.
If adjusted analyses are available (ANCOVA), we will use these as
a preference in our meta-analyses. If both changes from baseline
and endpoint scores are available for continuous data, we will
use change from baseline unless we note low correlation between
measurements in individuals. In addition, we will not combine
change from baseline and endpoint scores in analyses using the
SMD. If a study reports outcomes at multiple time points, we will
use the measure taken at the last follow-up. We will use the SDs
of final (rather than baseline) measurements in the analysis.
We will use intention-to-treat (ITT) or ’full analysis set’ analyses
when they are reported (i.e. those inwhich data have been imputed
for participants whowere randomly assigned but did not complete
the study) in preference to available case or per-protocol analyses,
if both are reported.
Unit of analysis issues
For dichotomous outcomes, we will use participants, rather than
events, as the unit of analysis (i.e. number of children admitted to
hospital rather than number of admissions per child). However, if
rate ratios are reported in a study (e.g. for exacerbations), we will
analyse them on this basis. We will meta-analyse data from cluster-
RCTs only if available data have been adjusted (or can be adjusted)
to account for the clustering. In keeping with recommendations
from the Cochrane Handbook for Systemaitc Reviews of Interven-
tions, we will adjust cluster-randomised data by inflating standard
errors using a design effect (DE) calculated with an intracluster
correlation coefficient (ICC).
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study is identified as an abstract only).
When this is not possible and the missing data are thought to
introduce serious bias, we will exclude the study.
Assessment of heterogeneity
We will use the Chi2 test of homogeneity and the I2 statistic to
measure heterogeneity among the studies included in each analysis.
If we identify substantial heterogeneity, we will report this and will
explore the possible causes by performing prespecified subgroup
analysis. Higgins et al suggests using an I2 value of 75% and over
to indicate high heterogeneity (Higgins 2003).
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small-study and publi-
cation biases using Egger’s t-test.
Data synthesis
We will use a random-effects model and will perform a sensitivity
analysis using a fixed-effect model.
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’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes: adherence to maintenance medication; asthma control
via any validated self-report instrument; exacerbations requiring
at least oral corticosteroid treatment; acceptability of the digital
intervention; unscheduled healthcare utilisation; time off school,
work, or other commitments due to asthma exacerbations or com-
plications; and any reported adverse events.
We will use the five GRADE considerations (risk of bias, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence as it relates to stud-
ies that contribute data for the prespecified outcomes. We will
use the methods and recommendations described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), using GRADEpro software
(GRADEproGDT).Wewill justify all decisions to downgrade the
quality of studies by using footnotes, and we will make comments
to aid the reader’s understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Interventions that have used only one digital component
versus interventions with multiple (more than one) digital
component.
2. Different types of digital interventions (i.e. online vs
computer-based vs electronic monitoring devices).
3. Interventions with an interactive component versus non-
interactive interventions.
4. Digital interventions involving adherence feedback versus
interventions that do not.
5. Theory-based versus non-theory-based digital
interventions.
6. Interventions for ICS versus non-ICS therapies.
7. Primary versus secondary care setting (defined in terms of
where participants were recruited for the study).
8. Interventions with an ’in-person’ component versus
interventions that are fully digital and self-delivered.
We will use the primary outcomes in the subgroup analyses.
1. Adherence to maintenance medication via any objective or
validated subjective measure of adherence.
2. Asthma control via any validated self-report instrument.
3. Exacerbations requiring at least oral corticosteroid
treatment.
We will use the formal test for subgroup interactions available in
Review Manager (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses while re-
moving these items from primary outcome analyses.
1. Unpublished data.
2. Trials with high risk of selection bias.
3. Trials via subjective adherence outcome measurement
methods.
4. Quasi-randomised trials.
5. Non-English studies.
6. Commercially funded studies.
We will compare results from a fixed-effect model versus results
from a random-effects model.
For cluster-randomised trials, we will run the main analyses using
more and less conservative estimates of the ICC.
A C K N OW L E D G E M E N T S
The Background and Methods sections of this protocol are based
on a standard template used by Cochrane Airways. The first back-
ground section of this protocol has been based on the published
Cochrane review ”Interventions to improve adherence to inhaled
steroids for asthma“ (Normansell 2017).
The authors of this work are affiliated with the Asthma UK Cen-
tre of Applied Research (AUKCAR), Queen Mary University of
London, and University College London.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Air-
ways. The views and opinions expressed therein are those of the re-
view authors and do not necessarily reflect those of the Systematic
Reviews Programme, NIHR, NHS, or the Department of Health.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify studies for the Cochrane Airways Trials Register
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp ”clinical trial [publication type]“/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
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8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify studies in other electronic databases.
Appendix 2. Search strategy to identify relevant studies from the Cochrane Airways Trials Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MESH DESCRIPTOR Web Browser
#6 MESH DESCRIPTOR Patient Portals
#7 MESH DESCRIPTOR Online Systems EXPLODE ALL
#8 MESH DESCRIPTOR Internet EXPLODE ALL
#9 (online* OR web* OR browser OR portal OR internet* OR virtual*):ti,ab,kw
#10 MESH DESCRIPTOR Cell Phones EXPLODE ALL
#11 MESH DESCRIPTOR MP3-Player
#12 MESH DESCRIPTOR Computer Systems EXPLODE ALL
#13 MESH DESCRIPTOR Mobile Applications
#14 ((cell* or mobile*) near3 phone*):ti,ab,kw
#15 (handheld* or hand-held*):ti,ab,kw
#16 (smartphone* or smart-phone*):ti,ab,kw
#17 (personal* near3 digital*):ti,ab,kw
#18 (PDA OR ”Palm OS“ or ”Palm Pre classic“ OR blackberry OR nokia OR symbian OR INQ OR HTC OR sidekick OR
android*OR iphone* OR ipod*OR ipad* OR samsung ORHuawei OR sonyORLGORpixel OR (windows* near3 (mobile*
or phone*)) OR (tablet near3 (device* or comput*))):ti,ab,kw
#19 (app* near3 (smartphone* or smart-phone or mobile* or phone* or tablet* or computer*)):ti,ab,kw
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(Continued)
#20 MESH DESCRIPTOR Text Messaging
#21 (sms OR mms):ti,ab,kw
#22 ((text* OR short*) NEAR3 messag*):ti,ab,kw
#23 texting:ti,ab,kw
#24 MESH DESCRIPTOR Reminder Systems EXPLODE ALL
#25 ((electronic* OR medication*) NEAR3 (reminder* OR monitor* or record* OR system* OR device*)):ti,ab,kw
#26 (reminder NEAR3 (text* or system* or messag*)):ti,ab,kw
#27 alert*:ti,ab,kw
#28 wearable*:ti,ab,kw
#29 MESH DESCRIPTOR Speech Recognition Software EXPLODE ALL
#30 ((interact* OR speech* OR voice* or touchtone) NEAR3 (recogni* OR respon*)):ti,ab,kw
#31 IVR:ti,ab,kw
#32 automat* NEAR3 (phone* or telephone* or call* OR system*):ti,ab,kw
#33 MESH DESCRIPTOR Communications Media EXPLODE ALL
#34 (”social media“ OR Facebook OR Twitter OR Instagram OR Snapchat OR YouTube ORWhatsApp):ti,ab,kw
#35 (video* OR television OR radio OR media* OR multimedia OR multi-media OR audio* OR webinar* OR podcast* OR
wiki* OR interactive OR digital* OR tech*) :ti,ab.kw
#36 MESH DESCRIPTOR Telemedicine EXPLODE ALL
#37 MESH DESCRIPTOR Telenursing EXPLODE ALL
#38 (telehealth* or tele-health* or telecare* or tele-care*):ti,ab,kw
#39 (mhealth or m-health or ”m health“ or ”mobile health“):ti,ab,kw
#40 (e-health or ehealth or ”e health“):ti,ab,kw
#41 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19
OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33
OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
#42 #41 AND #4
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(Continued)
#43 INREGISTER
#44 #43 AND #42
C O N T R I B U T I O N S O F A U T H O R S
Chan A: draft the protocol; develop and run search strategy; obtain copies of studies; select which studies to include; extract data from
studies, enter data into RevMan; carry out and interpret analysis; draft final review; update review.
De Simoni A: draft the protocol; develop and run search strategy; obtain copies of studies; select which studies to include; extract data
from studies; enter data into RevMan; carry out and interpret analysis; draft final review.
Wileman V: draft the protocol; develop and run search strategy; obtain copies of studies; select which studies to include; extract data
from studies; enter data into RevMan; carry out and interpret analysis; draft final review.
Holliday L: draft the protocol; develop and run search strategy; obtain copies of studies; select which studies to include; extract data
from studies; enter data into RevMan; carry out and interpret analysis; draft final review.
Chisari C: draft the protocol; develop and run search strategy; obtain copies of studies; select which studies to include; extract data
from studies; enter data into RevMan; draft final review.
Newby C: draft the protocol; carry out and interpret analysis; draft final review.
Fleming L: review the protocol; review final review.
Taylor SJC: review the protocol; review final review.
Griffiths C: review the protocol; review final review.
Horne R: review the protocol; review final review; update review.
D E C L A R A T I O N S O F I N T E R E S T
Chan A: Amy Chan has received consultancy fees from Janssen-Cilag, speaker fees from Novartis, and travel grants from Maurice
Phyllis Paykel Trust and Max Health for activities outside this submitted work. Amy is also a freelance consultant for the UCL-Business
spin-out Spoonful of Sugar Limited.
De Simoni A: none.
Wileman V: none.
Holliday L: none.
Chisari C: none.
Newby C: none.
Fleming L: consultancy fees fromVectura, advisory board fees fromBoehringer Ingleheim andNovartis: paid tomy Institution; personal
speakers fees from Novartis and AstraZeneca.
Taylor SJC: none.
Griffiths C: none.
Horne R: personal fees from AbbVie, Amgen, Biogen, Idec, Gilead Sciences, GlaxoSmithKline; personal fees from Janssen, Pfizer,
Roche, Shire Pharmaceuticals, MSD, Astellas, AstraZeneca, DRSU, Novartis, Universitatsklinikum Hamburg-Eppendorf; cofounder
of UCL-Business spin-out Spoonful of Sugar Limited.
17Digital interventions to improve adherence to maintenance medication in asthma (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S O U R C E S O F S U P P O R T
Internal sources
• University College London, UK.
Authors AC, VW, CC, and RH are employed by the UCL and are completing this review whilst employed by this institution.
• Queen Mary University, UK.
ADS, LH, CN, SJCT, and CG are researchers at the Centre for Primary Care and Public Health, Queen Mary University of London,
and are completing this review whilst employed by this institution.
• Royal Brompton Hospital, UK.
LF is employed by the Royal Brompton Hospital and is completing this review whilst employed at this institution.
External sources
• Asthma UK Centre of Applied Research, UK.
Authors AC, ADS, CN, SJCT, LF, CG, and RH on this review are researchers affiliated with, and supported by, AUKCAR.
• National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLARHC)
North Thames at Bart’s Health NHS Trust, UK.
RH, SJCT, and CG are supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied
Health Research and Care (CLAHRC) North Thames at Bart’s Health NHS Trust.
The views expressed are those of the review authors and are not necessarily those of the NHS, the NIHR, or the Department of
Health.
• No such funding has been specifically received for this review, Other.
18Digital interventions to improve adherence to maintenance medication in asthma (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
